Excision of the A1 pulley for Trigger Thumb

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Trigger Thumb+1 More
Excision of the A1 pulley - Procedure
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is investigating whether excision or incision of the A1 pulley is more effective for trigger finger surgery, in terms of recurrence rates, pain relief, and patient-reported outcomes.

Eligible Conditions
  • Trigger Thumb
  • Trigger Finger

Treatment Effectiveness

Study Objectives

2 Primary · 9 Secondary · Reporting Duration: Baseline, 2 weeks, 6 weeks, 3 months, 6 months, and 1 year

Year 1
Change in patients' reported Working status
Change in patients' reported demand of daily activities
Change in patients' reported pain interference subjective score in social activities
Change in patients' reported pain interference subjective score in the day-to-day activities
Change in patients' reported quantity of pain medication pills per day
Change in patients' reported satisfaction
Change in patients' reported side effects from pain medications
Change in the pain score
Change in the range of motion
Changes in the number of participants using pain medication
Recurrent trigger finger after A1 pulley release

Trial Safety

Trial Design

2 Treatment Groups

incision of the A1 pulley in the standard fashion
1 of 2
excision of the A1 pulley
1 of 2
Active Control
Experimental Treatment

500 Total Participants · 2 Treatment Groups

Primary Treatment: Excision of the A1 pulley · No Placebo Group · N/A

excision of the A1 pulley
Procedure
Experimental Group · 1 Intervention: Excision of the A1 pulley · Intervention Types: Procedure
incision of the A1 pulley in the standard fashion
Procedure
ActiveComparator Group · 1 Intervention: Incision of the A1 pulley in the standard fashion · Intervention Types: Procedure

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, 2 weeks, 6 weeks, 3 months, 6 months, and 1 year

Who is running the clinical trial?

Emory UniversityLead Sponsor
1,501 Previous Clinical Trials
2,677,056 Total Patients Enrolled
Eric Wagner, MD, MSPrincipal InvestigatorEmory University

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 6th, 2021

Last Reviewed: October 19th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.